1. Blocking of interleukin-1 suppresses angiotensin II-induced renal injury
- Author
-
Sarasa Isobe, Kazunori Shimada, Koji Akita, Motoaki Sano, Tohru Minamino, Yoichiro Iwakura, Tomiharu Niida, Kikuo Isoda, Yayoi Sato-Okabayashi, and Fumie Ohtomo
- Subjects
Endothelin Receptor Antagonists ,medicine.medical_specialty ,medicine.drug_class ,Interleukin-1beta ,Renal function ,Blood Pressure ,Inflammation ,Kidney ,Antibodies ,Proinflammatory cytokine ,Fibrosis ,Internal medicine ,Renin–angiotensin system ,medicine ,Animals ,Humans ,Mice, Knockout ,Endothelin-1 ,business.industry ,Angiotensin II ,Interleukin ,Bosentan ,General Medicine ,Receptor antagonist ,medicine.disease ,Mice, Inbred C57BL ,Disease Models, Animal ,Interleukin 1 Receptor Antagonist Protein ,Endocrinology ,Hypertension ,Kidney Diseases ,medicine.symptom ,business ,Signal Transduction - Abstract
Clinical hypertension (HT) is associated with renal inflammation and elevated circulating levels of proinflammatory cytokines. Interleukin (IL)-1 receptor antagonist (IL-1Ra) is one of the most important anti-inflammatory cytokines and plays a crucial role in inflammation. Inhibition of IL-1 may contribute to modulation of the Angiotensin II (Ang II)-induced HT response. The present study aimed to elucidate the effects of IL-1Ra and anti-IL-1β antibody (01BSUR) on Ang II-induced renal injury. To determine the contribution of IL-1Ra to Ang II-induced renal inflammation, male wildtype (WT) and IL-1Ra-deficient (IL-1Ra−/−) mice were infused with Ang II (1000 ng/kg/min) using subcutaneous osmotic pump for 14 days. We checked renal function, histological change, and several mRNA expressions 14 days after infusion. Fourteen days after infusion, systolic blood pressure (197 ± 5 vs 169 ± 9 mmHg, P
- Published
- 2021